Monthly Archives: December 2021

IPR decision finding Quest’s testosterone-detection claims obvious affirmed

Posted on December 31, 2021 by Patrick J. Halloran, Ph.D., J.D.

Quest Diagnostics Investments LLC v. USPTO Docket No. 2021-1115 (IPR2019-00738) (https://cafc.uscourts.gov/opinions-orders/21-1115.OPINION.12-27-2021_1885462.pdf) (Non-Precedential) MOORE, CLEVENGER, STOLL December 27, 2021 Brief Summary:  Board IPR decision of anticipation and obviousness of Quest’s claims affirmed. Summary:  Quest appealed Board IPR decision that the challenged … Continue reading →

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

DC finding that Polymetrix did not induce importation of samples into the US affirmed

Posted on December 27, 2021 by Patrick J. Halloran, Ph.D., J.D.

Alpek Polyester, S.A., DAK Americas LLC, et al. v. Polymetrix AG Docket No. 2021-1706 (https://cafc.uscourts.gov/opinions-orders/21-1706.OPINION.12-16-2021_1880727.pdf) (Non-precedential) LOURIE, O’MALLEY, STOLL December 16, 2021 Brief Summary:  DC grant of SJ of no induced infringement by importation affirmed. Summary:  Alpek/DAK appealed DC grant … Continue reading →

Posted in Importation, Inducement to Infringe, Infringement, Licensing | Leave a comment

IPR decision finding Moderna did not show Arbutus claims obvious affirmed

Posted on December 22, 2021 by Patrick J. Halloran, Ph.D., J.D.

Moderna Therapeutics, Inc. et al. v. Arbutus Biopharma Corp. Docket No. 2020-2329 (IPR2-19-00554) (https://cafc.uscourts.gov/opinions-orders/20-2329.OPINION.12-1-2021_1872458.pdf) LOURIE, O’MALLEY, STOLL December 1, 2021 Brief Summary:  Board IPR decision of non-obviousness affirmed. Summary:  Moderna appealed USPTO (“Board”) IPR holding the claims of US 8,058,069 … Continue reading →

Posted in Anticipation (35 USC 102), Appeal, Article III disputes, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

IPR decision finding Moderna did not show Arbutus claims obvious affirmed

Posted on December 22, 2021 by Patrick J. Halloran, Ph.D., J.D.

Moderna Therapeutics, Inc. et al. v. Arbutus Biopharma Corp. Docket No. 2020-2329 (IPR2-19-00554) (https://cafc.uscourts.gov/opinions-orders/20-2329.OPINION.12-1-2021_1872458.pdf) LOURIE, O’MALLEY, STOLL December 1, 2021 Brief Summary:  Board IPR decision of non-obviousness affirmed. Summary:  Moderna appealed USPTO (“Board”) IPR holding the claims of US 8,058,069 … Continue reading →

Posted in Anticipation (35 USC 102), Appeal, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Single mention of dose at lower end of range is insufficient written description, DC decision affirmed

Posted on December 3, 2021 by Patrick J. Halloran, Ph.D., J.D.

Biogen International GmbH et al. v. Mylan Pharmaceuticals Inc. Docket No. 2020-1933 (https://cafc.uscourts.gov/opinions-orders/20-1933.OPINION.11-30-2021_1871902.pdf) O’MALLEY (dissent), REYNA, HUGHES November 30, 2021 Brief Summary:  DC decision finding a lack of written description based on “[t]he specification’s sole reference to” the claimed dosage … Continue reading →

Posted in Generics / ANDA, Inter Parties Review (IPR), IPR, Written description | Leave a comment